ALLMedicine™ Plaque Psoriasis Center

Aug 2nd, 2021 - Topical treatment is the mainstay for mild or moderate psoriasis, but patients are generally little satisfied. Calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam has shown to improve signs and symptoms in plaque psoriasis patients. Th...

Jul 30th, 2021 - Plaque psoriasis has been associated with anxiety, depression, suicidal ideation and various personality traits. However, studies on hypochondriasis, i.e. the belief of serious illness despite having no or only mild symptoms, are currently scarce....

Jul 23rd, 2021 - Dimethyl fumarate (DMF) is a fumaric acid esters derivate approved for plaque psoriasis as first-line systemic therapy. It has been available in Italy since 2017 and an increasing number of patients are treated with this drug. To evaluate DMF effe...

Jul 22nd, 2021 - Psoriasis is a common chronic and complex inflammatory skin disease that affects over 125 million people worldwide. Management of psoriasis in daily clinical practice in Saudi Arabia is variable. Local preferences for management differ, which may ...

Jul 22nd, 2021 - Psoriasis is a long-lasting, inflammatory disease of the skin with not fully understood pathogenesis. Uncoupling protein 2 (UCP2) and dynamin-related protein 1 (Drp1) are the main mitochondrial regulatory proteins implicated in various inflammator...

Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

May 7th, 2020 - This is a phase 2, multicenter, open-label, study to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy of Apremilast in participants with recalcitrant plaque-type psoriasis. Approximately 31 participants were enrol...

May 7th, 2020 - Each subject will undergo a screening period of up to 5 weeks, a treatment period of 2 weeks with PK sample collection, and an extension treatment period of 48 weeks, to allow subjects access to apremilast treatment if medically appropriate (follo...

Apr 24th, 2020 - There are 2 cohorts of subjects. Cohort 1 is a single dose study of ARQ-151 0.5% cream applied to 25 cm2 of psoriatic plaque(s) in up to 8 psoriasis subjects. Cohort 2 is a parallel group, double blind, vehicle controlled study in which ARQ-151 cr...

Apr 20th, 2020 - The study will consist of four phases: Screening Phase - up to 35 days Double-blind Placebo-controlled Phase - Weeks 0 to 16 - Subjects will be randomly assigned to either apremilast 30 mg tablets orally BID or placebo tablets (identical in appear...

Apr 17th, 2020 - Treatment will be assigned by weight with subjects 20 kg to < 50 kg receiving apremilast 20 mg BID or placebo BID and subjects ≥ 50 kg receiving apremilast 30 mg BID or placebo BID. Total study duration is up to 71 weeks. Subjects completing all 5...

Jul 9th, 2021 - Psoriasis is a chronic, immune-mediated inflammatory skin disease. Globally, approximately 125 million people have psoriasis, which manifests in several ways (ie, plaque, flexural, guttate, pustular, or erythrodermic psoriasis). Plaque psoriasis i...

Jul 9th, 2021 - Plaque psoriasis is the most common form of psoriasis, a chronic inflammatory skin disorder that affects approximately 125 million individuals worldwide. It exerts a considerable burden on affected patients, including decreased quality of life and...

Jun 24th, 2021 - Patients with psoriasis treated with biological disease-modifying antirheumatic drugs had a significantly lower incidence of psoriatic arthritis (PsA) compared with those treated with phototherapy, in a study of 464 adults. Epidemiologic data show...

Jun 14th, 2021 - Approximately 125 million people around the world have psoriasis, a chronic, relapsing inflammatory skin disorder. Several clinical variants of psoriasis are recognized, but plaque psoriasis is the most common. Psoriasis is associated with a signi...

Jun 14th, 2021 - Approximately 125 million people around the world have psoriasis, a chronic, relapsing inflammatory skin disorder. Several clinical variants of psoriasis are recognized, but plaque psoriasis is the most common. Psoriasis is associated with a signi...